SlideShare ist ein Scribd-Unternehmen logo
1 von 10
RESTRICTED DRUGS
Risk Evaluation and Mitigation Strategies--REMS
With each drug/biologic safety issue posing a serious risk,
the question for FDA will be: to REM or not to REM?
REMS---Food and Drug Administration
Amendments Act of 2007
in 2006 the FDA listed 156 REMS for prescription
medicines (128) and biologics (28)
intended to ensure the benefits of the medication outweigh
its risk
why REMS??--Public outcry over revelations of
unforeseen risks from trusted medicines(rofecoxib,
valdecoxib, and salmeterol
RESTRICTED DRUGS
 FDA can require a manufacturer to implement a REMS
 Components of REMS
 1--Medication Guides--required for drugs and
biologics when the FDA determines that: (a) certain
information is necessary to prevent serious adverse
effects, (b) patient decision-making should be
informed by information about a known serious side
effect of a product, or (c) patient adherence to
directions for the use of a product is essential to its
effectiveness.
RESTRICTED DRUGS
 2--Communication Plans--
 Letters to healthcare providers;
 Disseminating information about the REMS to
encourage implementation; and
 Disseminating information through professional
societies about any serious risks of the drug and any
protocol to assure safe use.
RESTRICTED DRUGS
 3--Elements to Assure Safe Use(ETASU)
 may include one or more of the following
 Special training, certifications, or demonstration of
experience for prescribers of the drug/biologic
 Certification of pharmacies, practitioners, or healthcare
settings that dispense the drug/biologic
 Limitations as to the healthcare settings where the
drug/biologic may be dispensed
 Evidence of special safe-use conditions--patients receive the
drug/biologic only after specified authorization,proof of
counseling, periodic blood tests
 monitor the number of prescriptions dispensed, adverse
events,
Examples of Drugs with REMS
 alosetron (Lotronex)
 clozapine (Clozaril, Fazaclo)
 isotretinoin (Accutane, Amnesteem,
Claravis, Sotret)
 thalidomide (Thalomid)
 dofetilide (Tikosyn)
Alosetron
 Treats a type of irritable bowel syndrome (IBS)
 Serious adverse reactions of gastrointestinal
tract
 some necessitate a blood transfusion or surgery
 some even lead to death
 Restricted by Prescription Program for
Lotronex (PPL)
 requires physician enrollment & submission of Patient-
Physician Agreement Form
 Prescriptions must be written by physician & must
include PPL sticker on face of prescription
Clozapine
 Treats patients with schizophrenia
 Can cause serious drop in white blood cells
 monitoring must be done regularly
 Pharmacies must register to dispense
clozapine
 Specific day supply may be dispensed
 (1, 2, or 3 weeks depending on monitoring
frequency)
 Pharmacy must receive documentation of
blood work
Isotretinoin
 Treats severe acne & can cause serious birth
defects
 iPledge Program
 registration required by
 doctors
 patients
 Pharmacies
 must meet specific requirements / answer
questions with iPledge Program each time drug
dispensed
 quantity dispensed is limited
 prescription must be picked up within limited
Thalidomide
 Treats multiple myeloma/erythema nodosum
leprosum
 Causes birth defects
 Thalidomide Education & Prescribing
Safety (S.T.E.P.S.) Program
 prescribers, patients, pharmacies must register
 pharmacy must verify that the prescriber is
registered with S.T.E.P.S. before dispensing
medication
Dofetilide
 Treats irregular heart rhythms
 Can cause serious complications
 Patients must be hospitalized to initiate
therapy
 Tikosyn in Pharmacy System (T.I.P.S.)
 prescribers & pharmacists must register
 pharmacy must verify the prescriber’s
registration

Weitere ähnliche Inhalte

Was ist angesagt?

Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsCombination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsMichael Swit
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safetyLanre Suleiman
 
Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossierDeeptiGupta154
 
Q1 2018 earnings charts final
Q1 2018 earnings charts   finalQ1 2018 earnings charts   final
Q1 2018 earnings charts finalpfizer_ir
 
FDA Regulation of Combination Products
FDA Regulation of Combination ProductsFDA Regulation of Combination Products
FDA Regulation of Combination ProductsMichael Swit
 
Reference Regulatory Authorities for Registration of Products in Drug Regula...
Reference Regulatory Authorities for Registration of Products in  Drug Regula...Reference Regulatory Authorities for Registration of Products in  Drug Regula...
Reference Regulatory Authorities for Registration of Products in Drug Regula...Arooj Abid
 
Drug Quality and Security Act
Drug Quality and Security ActDrug Quality and Security Act
Drug Quality and Security ActBen Comer
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRAManikant Prasad Shah
 
Controlled drugs
Controlled drugsControlled drugs
Controlled drugsDarya Daoud
 
Galena presentation 22 sept 16
Galena presentation   22 sept 16Galena presentation   22 sept 16
Galena presentation 22 sept 16Galenabio
 
Bellus corporate presentation march 23
Bellus corporate presentation march 23Bellus corporate presentation march 23
Bellus corporate presentation march 23BellusHealth
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16Galenabio
 
21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)AshishVerma593
 
Bellus health presentation september 14, 2017
Bellus health presentation   september 14, 2017Bellus health presentation   september 14, 2017
Bellus health presentation september 14, 2017BellusHealth
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16 Galenabio
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...DoriaFang
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 

Was ist angesagt? (18)

Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsCombination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC Drugs
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safety
 
Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossier
 
Q1 2018 earnings charts final
Q1 2018 earnings charts   finalQ1 2018 earnings charts   final
Q1 2018 earnings charts final
 
FDA Regulation of Combination Products
FDA Regulation of Combination ProductsFDA Regulation of Combination Products
FDA Regulation of Combination Products
 
Reference Regulatory Authorities for Registration of Products in Drug Regula...
Reference Regulatory Authorities for Registration of Products in  Drug Regula...Reference Regulatory Authorities for Registration of Products in  Drug Regula...
Reference Regulatory Authorities for Registration of Products in Drug Regula...
 
Data exclusivity
Data exclusivityData exclusivity
Data exclusivity
 
Drug Quality and Security Act
Drug Quality and Security ActDrug Quality and Security Act
Drug Quality and Security Act
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
 
Controlled drugs
Controlled drugsControlled drugs
Controlled drugs
 
Galena presentation 22 sept 16
Galena presentation   22 sept 16Galena presentation   22 sept 16
Galena presentation 22 sept 16
 
Bellus corporate presentation march 23
Bellus corporate presentation march 23Bellus corporate presentation march 23
Bellus corporate presentation march 23
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16
 
21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)
 
Bellus health presentation september 14, 2017
Bellus health presentation   september 14, 2017Bellus health presentation   september 14, 2017
Bellus health presentation september 14, 2017
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 

Andere mochten auch

Rems Presentation for FDA
Rems Presentation for FDARems Presentation for FDA
Rems Presentation for FDAmvilaret
 
REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting youDavid Levin
 
Medical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel DiseaseMedical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel DiseaseBenjamin Gelassen, MBA
 
Psoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized ApproachPsoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized ApproachIFSMED
 
Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)Hussien Salam
 
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...hivlifeinfo
 
Harvoni and Hepatitis C revised
Harvoni and Hepatitis C revisedHarvoni and Hepatitis C revised
Harvoni and Hepatitis C revisedThomas Huang
 
BIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISBIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISDr. Sachin Kumar
 

Andere mochten auch (13)

Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
Rems Presentation for FDA
Rems Presentation for FDARems Presentation for FDA
Rems Presentation for FDA
 
REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting you
 
N334 ACR Hammond
N334 ACR HammondN334 ACR Hammond
N334 ACR Hammond
 
Medical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel DiseaseMedical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel Disease
 
2015 Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
2015   Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...2015   Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
2015 Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
 
Presentation
PresentationPresentation
Presentation
 
Psoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized ApproachPsoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized Approach
 
Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)
 
Relapse.Remitting.MS
Relapse.Remitting.MSRelapse.Remitting.MS
Relapse.Remitting.MS
 
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
 
Harvoni and Hepatitis C revised
Harvoni and Hepatitis C revisedHarvoni and Hepatitis C revised
Harvoni and Hepatitis C revised
 
BIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISBIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITIS
 

Ähnlich wie Restricteddrugpate

MANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALSMANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALSDr.Jeena Salim
 
Cassualty assesment of adr
Cassualty assesment of adrCassualty assesment of adr
Cassualty assesment of adrmohamed abusalih
 
Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ ClassicJoseph Gut
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilancesiddemsetty nikhil
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaUntil ROI
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance ANAhmed Nouri
 
Adverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLSAdverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLSKatalyst HLS
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaSynthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaIJARIIT
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaBishnu Koirala
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringVenugopal N
 
Towards Personalized Medicine
Towards Personalized MedicineTowards Personalized Medicine
Towards Personalized MedicineMichel Dumontier
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized MedicineMichel Dumontier
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxKarismaDash1
 
ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017Louis Bock
 

Ähnlich wie Restricteddrugpate (20)

MANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALSMANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALS
 
Hospital pharmacy
Hospital pharmacyHospital pharmacy
Hospital pharmacy
 
Cassualty assesment of adr
Cassualty assesment of adrCassualty assesment of adr
Cassualty assesment of adr
 
Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ Classic
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilance
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, Cipla
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Adverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLSAdverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLS
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaSynthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
 
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand PirouziHealth Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koirala
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
 
Towards Personalized Medicine
Towards Personalized MedicineTowards Personalized Medicine
Towards Personalized Medicine
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptx
 
ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017
 

Mehr von cqpate

Urinary noyouranary 2
Urinary noyouranary 2Urinary noyouranary 2
Urinary noyouranary 2cqpate
 
Corticosteroids
CorticosteroidsCorticosteroids
Corticosteroidscqpate
 
Antihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorantsAntihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorantscqpate
 
Firstaid
FirstaidFirstaid
Firstaidcqpate
 
Sterile enviroment
Sterile enviromentSterile enviroment
Sterile enviromentcqpate
 
Rx order
Rx orderRx order
Rx ordercqpate
 
Retaildelivery
RetaildeliveryRetaildelivery
Retaildeliverycqpate
 
Regulatgion audit
Regulatgion auditRegulatgion audit
Regulatgion auditcqpate
 
Recordkeeping
RecordkeepingRecordkeeping
Recordkeepingcqpate
 
Recallsrefund
RecallsrefundRecallsrefund
Recallsrefundcqpate
 
Pointof saleinvenrtory
Pointof saleinvenrtoryPointof saleinvenrtory
Pointof saleinvenrtorycqpate
 
Effectofmeds
EffectofmedsEffectofmeds
Effectofmedscqpate
 
Hospital drug rx
Hospital drug rxHospital drug rx
Hospital drug rxcqpate
 
Hospdelivery
HospdeliveryHospdelivery
Hospdeliverycqpate
 
Pharmadmin
PharmadminPharmadmin
Pharmadmincqpate
 
Analgesics
AnalgesicsAnalgesics
Analgesicscqpate
 
Respiratorydrugs
RespiratorydrugsRespiratorydrugs
Respiratorydrugscqpate
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemiacqpate
 
Cardiovascularagentsnew
CardiovascularagentsnewCardiovascularagentsnew
Cardiovascularagentsnewcqpate
 

Mehr von cqpate (20)

STD
STDSTD
STD
 
Urinary noyouranary 2
Urinary noyouranary 2Urinary noyouranary 2
Urinary noyouranary 2
 
Corticosteroids
CorticosteroidsCorticosteroids
Corticosteroids
 
Antihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorantsAntihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorants
 
Firstaid
FirstaidFirstaid
Firstaid
 
Sterile enviroment
Sterile enviromentSterile enviroment
Sterile enviroment
 
Rx order
Rx orderRx order
Rx order
 
Retaildelivery
RetaildeliveryRetaildelivery
Retaildelivery
 
Regulatgion audit
Regulatgion auditRegulatgion audit
Regulatgion audit
 
Recordkeeping
RecordkeepingRecordkeeping
Recordkeeping
 
Recallsrefund
RecallsrefundRecallsrefund
Recallsrefund
 
Pointof saleinvenrtory
Pointof saleinvenrtoryPointof saleinvenrtory
Pointof saleinvenrtory
 
Effectofmeds
EffectofmedsEffectofmeds
Effectofmeds
 
Hospital drug rx
Hospital drug rxHospital drug rx
Hospital drug rx
 
Hospdelivery
HospdeliveryHospdelivery
Hospdelivery
 
Pharmadmin
PharmadminPharmadmin
Pharmadmin
 
Analgesics
AnalgesicsAnalgesics
Analgesics
 
Respiratorydrugs
RespiratorydrugsRespiratorydrugs
Respiratorydrugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Cardiovascularagentsnew
CardiovascularagentsnewCardiovascularagentsnew
Cardiovascularagentsnew
 

Kürzlich hochgeladen

Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIShubhangi Sonawane
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docxPoojaSen20
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxNikitaBankoti2
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Shubhangi Sonawane
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 

Kürzlich hochgeladen (20)

Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptx
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 

Restricteddrugpate

  • 1. RESTRICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS With each drug/biologic safety issue posing a serious risk, the question for FDA will be: to REM or not to REM? REMS---Food and Drug Administration Amendments Act of 2007 in 2006 the FDA listed 156 REMS for prescription medicines (128) and biologics (28) intended to ensure the benefits of the medication outweigh its risk why REMS??--Public outcry over revelations of unforeseen risks from trusted medicines(rofecoxib, valdecoxib, and salmeterol
  • 2. RESTRICTED DRUGS  FDA can require a manufacturer to implement a REMS  Components of REMS  1--Medication Guides--required for drugs and biologics when the FDA determines that: (a) certain information is necessary to prevent serious adverse effects, (b) patient decision-making should be informed by information about a known serious side effect of a product, or (c) patient adherence to directions for the use of a product is essential to its effectiveness.
  • 3. RESTRICTED DRUGS  2--Communication Plans--  Letters to healthcare providers;  Disseminating information about the REMS to encourage implementation; and  Disseminating information through professional societies about any serious risks of the drug and any protocol to assure safe use.
  • 4. RESTRICTED DRUGS  3--Elements to Assure Safe Use(ETASU)  may include one or more of the following  Special training, certifications, or demonstration of experience for prescribers of the drug/biologic  Certification of pharmacies, practitioners, or healthcare settings that dispense the drug/biologic  Limitations as to the healthcare settings where the drug/biologic may be dispensed  Evidence of special safe-use conditions--patients receive the drug/biologic only after specified authorization,proof of counseling, periodic blood tests  monitor the number of prescriptions dispensed, adverse events,
  • 5. Examples of Drugs with REMS  alosetron (Lotronex)  clozapine (Clozaril, Fazaclo)  isotretinoin (Accutane, Amnesteem, Claravis, Sotret)  thalidomide (Thalomid)  dofetilide (Tikosyn)
  • 6. Alosetron  Treats a type of irritable bowel syndrome (IBS)  Serious adverse reactions of gastrointestinal tract  some necessitate a blood transfusion or surgery  some even lead to death  Restricted by Prescription Program for Lotronex (PPL)  requires physician enrollment & submission of Patient- Physician Agreement Form  Prescriptions must be written by physician & must include PPL sticker on face of prescription
  • 7. Clozapine  Treats patients with schizophrenia  Can cause serious drop in white blood cells  monitoring must be done regularly  Pharmacies must register to dispense clozapine  Specific day supply may be dispensed  (1, 2, or 3 weeks depending on monitoring frequency)  Pharmacy must receive documentation of blood work
  • 8. Isotretinoin  Treats severe acne & can cause serious birth defects  iPledge Program  registration required by  doctors  patients  Pharmacies  must meet specific requirements / answer questions with iPledge Program each time drug dispensed  quantity dispensed is limited  prescription must be picked up within limited
  • 9. Thalidomide  Treats multiple myeloma/erythema nodosum leprosum  Causes birth defects  Thalidomide Education & Prescribing Safety (S.T.E.P.S.) Program  prescribers, patients, pharmacies must register  pharmacy must verify that the prescriber is registered with S.T.E.P.S. before dispensing medication
  • 10. Dofetilide  Treats irregular heart rhythms  Can cause serious complications  Patients must be hospitalized to initiate therapy  Tikosyn in Pharmacy System (T.I.P.S.)  prescribers & pharmacists must register  pharmacy must verify the prescriber’s registration